Have a personal or library account? Click to login
The clinically important anaerobic, human pathogenic Bacteroides species and their antibiotic resistance levels in Central and Southeast Europe Cover

The clinically important anaerobic, human pathogenic Bacteroides species and their antibiotic resistance levels in Central and Southeast Europe

Open Access
|Jan 2019

References

  1. 1. Wexler HM. Bacteroides: the good, the bad and the nittygritty. Clin Microbiol Rev. 2007;20(4):593-621.10.1128/CMR.00008-07217604517934076
  2. 2. Könönen E, Wade WG, Citron DM. Bacteroides, Porphyromonas, Prevotella, Fusobacterium, and other anaerobic Gram-negative rods. Manual of Clinical Microbiology, 10th Edition: American Society of Microbiology; 2011.10.1128/9781555816728.ch51
  3. 3. Nagy E. Anaerobic infections: Update on treatment considerations. Drugs. 2010;70(7):841-58.10.2165/11534490-000000000-000002042649620426496
  4. 4. Sóki J. Extended role for insertion sequence elements in the antibiotic resistance of Bacteroides. World Journal of Clinical Infectious Diseases. 2013;3(1):1-12.10.5495/wjcid.v3.i1
  5. 5. Sóki J, Wareham DW, Rátkai C, Aduse-Opoku J, Urbán E, Nagy E. Prevalence, nucleotide sequence and expression studies of two proteins of a 5.6 kb, Class III, Bacteroides plasmid frequently found in clinical isolates from European countries. Plasmid. 2010;63(2):86-97.10.1016/j.plasmid.2009.12.00220026106
  6. 6. Rasmussen BA, Bush K, Tally FP. Antimicrobial resistance in Bacteroides. Clinical Infectious Diseases. 1993;16:S390-400.10.1093/clinids/16.Supplement_4.S3908324154
  7. 7. Clinical breakpoints [database on the Internet]. European Committee on Antimicrobial Susceptibility Testing (EUCAST). 2015-01. Available from: www.eucast.org/clinical:beakpoints/.
  8. 8. Methods for antimicrobial susceptibility testing of anaerobic bacteria, Approved Standard, Document M11-A8 Clinical Laboratory Standards Institute, Wayne PA,; 2012.
  9. 9. Nagy E, Justesen US, Eitel Z, Urbán E. Development of EUCAST disk diffusion method for susceptibility testing of the Bacteroides fragilis group isolates. Anaerobe. 2015;31:65-71.10.1016/j.anaerobe.2014.10.00825464140
  10. 10. Nagy E, Maier T, Urban E, Terhes G, Kostrzewa M. Species identification of clinical isolates of Bacteroides by matrix-assisted laser-desorption/ionization time-of-flight mass spectrometry. Clinical Microbiology and Infection. 2009;15(8):796-802.10.1111/j.1469-0691.2009.02788.x19438622
  11. 11. Nagy E, Becker S, Sóki J, Urbán E, Kostrzewa M. Differentiation of division I (cfiA-negative) and division II (cfiA-positive) Bacteroides fragilis strains by matrix-assisted laser desorption/ionization time of-flight mass spectrometry. Journal of Medical Microbiology. 2011;60(11):1584-90.10.1099/jmm.0.031336-021680764
  12. 12. Johansson Å, Nagy E, Sóki J. Detection of carbapenemase activities of Bacteroides fragilis strains with matrix-assisted laser desorption ionization – Time of flight mass spectrometry (MALDI-TOF MS). Anaerobe. 2014;26:49-52.10.1016/j.anaerobe.2014.01.00624480431
  13. 13. Snydman DR, Jacobus NV, McDermott LA, Ruthazer R, Golan Y, Goldstein EJC, et al. National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997-2004. Antimicrobial Agents and Chemotherapy. 2007;51(5):1649-55.10.1128/AAC.01435-06185553217283189
  14. 14. Snydman DR, Jacobus NV, McDermott LA, Golan Y, Goldstein EJC, Harrell L, et al. Update on resistance of Bacteroides fragilis group and related species with special attention to carbapenems 2006–2009. Anaerobe. 2011;17(4):147-51.10.1016/j.anaerobe.2011.05.01421664469
  15. 15. Snydman DR, Jacobus NV, McDermott LA, Golan Y, Hecht DW, Goldstein EJC, et al. Lessons learned from the anaerobe survey: Historical perspective and review of most recent data (2005-2007). Clinical Infectious Diseases. 2010;50(Suppl1):S26-33.10.1086/64794020067390
  16. 16. Philips I, King A, Nord CE, Hoffstedt B on behalf of the ESCMID Study Group on Antimicrobial Resistance of Anaerobic Bacteria. Antibiotic sensitivity of Bacteroides fragilis group in Europe. European Journal of Clinical Microbiology & Infectious Diseases. 1992;11(4):292-304.10.1007/BF019620681396748
  17. 17. Hedberg M, Nord CE on behalf of the ESCMID Study Group on Antimicrobial Resistance of Anaerobic Bacteria. Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe. Clinical Microbiology and Infection. 2003;9(6):475-88.10.1046/j.1469-0691.2003.00674.x12848722
  18. 18. Nagy E, Urbán E, Nord CE on behalf of the ESCMID Study Group on Antimicrobial Resistance of Anaerobic Bacteria. Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe 20 years of experience. Clinical Microbiology and Infection. 2011;17(3):371-9.10.1111/j.1469-0691.2010.03256.x20456453
  19. 19. Labbé A-C, Bourgault A-M, Vincelette J, Turgeon PL, Lamothe F. Trends in antimicrobial resistance among clinical isolates of the Bacteroides fragilis group from 1992 to 1997 in Montreal, Canada. Antimicrobial Agents and Chemotherapy. 1999;43(10):2517-9.10.1128/AAC.43.10.25178951110508035
  20. 20. Wybo I, Van den Bossche D, Soetens O, Vekens E, Vandoorslaer K, Claeys G, et al. Fourth Belgian multicentre survey of antibiotic susceptibility of anaerobic bacteria. Journal of Antimicrobial Chemotherapy. 2014 January 1, 2014;69(1):155-61.10.1093/jac/dkt344
  21. 21. Boyanova L, Kolarov R, Mitov I. Recent evolution of antibiotic resistance in the anaerobes as compared to previous decades. Anaerobe. 2015;31:4-10.10.1016/j.anaerobe.2014.05.00424875330
  22. 22. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clinical Microbiology and Infection. 2012;18(3):268-81.10.1111/j.1469-0691.2011.03570.x21793988
  23. 23. Hartmeyer GN, Sóki J, Nagy E, Justesen US. Multidrugresistant Bacteroides fragilis group on the rise in Europe? Journal of medical microbiology. 2012 December 1, 2012;61(Pt 12):1784-8.10.1099/jmm.0.049825-0
  24. 24. Katsandri A, Papaparaskevas J, Pantazatou A, Petrikkos GL, Thomopoulos G, Houhoula DP, et al. Two cases of infections due to multidrug-resistant Bacteroides fragilis group strains. Journal of Clinical Microbiology. 2006 September 1, 2006;44(9):3465-7.10.1128/JCM.00316-06
  25. 25. Urbán E, Horváth Z, Sóki J, Lázár G. First Hungarian case of an infection caused by multidrug-resistant Bacteroides fragilis strain. Anaerobe. 2015;31(0):55-8.10.1016/j.anaerobe.2014.09.01925285854
  26. 26. Cuchural G. J.; Tally FPJ, N. V.; Cleary, T.; Finegold, S. M.; Hill, G.; Iannini, P.; O’Keefe, P. O.; Pierson, C. Comparative activities od newer β-lactam agents against members of the Bacteroides fragilis group. Antimicrobial Agents and Chemotherapy. 1990;34(3):479-80.10.1128/AAC.34.3.4791716202334161
  27. 27. Snydman DR, Jacobus NV, McDermott LA. Evaluation of the in vitro activities of doripenem, a new broad spectrum carbapenem, against recent clinical anaerobic isolates with emphasis on the Bacteroides fragilis group. Antimicrobial Agents and Chemotherapy. 2008(Journal Article).10.1128/AAC.00696-08259288518838581
  28. 28. Marina M, Ivanova M, Kantardjiev T. Antimicrobial susceptibility of anaerobic bacteria in Bulgaria. Anaerobe. 2009;15(4):127-32.10.1016/j.anaerobe.2009.03.00219292999
  29. 29. Nagy E, Szőke I, Gacs M, Csiszár K. Antibiotic susceptibility of Bacteroides fragilis group strains in Hungary. Anaerobe. 1995 1995/10/01;1(5):269-74.10.1006/anae.1995.102616887535
  30. 30. Papaparaskevas J, Pantazatou A, Katsandri A, Legakis NJ, Avlamis A. Multicentre survey of the in-vitro activity of seven antimicrobial agents, including ertapenem, against recently isolated Gram-negative anaerobic bacteria in Greece. Clinical Microbiology and Infection. 2005;11(10):820-4.10.1111/j.1469-0691.2005.01233.x16153256
  31. 31. Papaparaskevas J, Pantazatou A, Katsandri A, Houhoula DP, Legakis NJ, Tsakris A, et al. Moxifloxacin resistance is prevalent among Bacteroides and Prevotella species in Greece. Journal of Antimicrobial Chemotherapy. 2008;62(1):137-41.10.1016/j.ijantimicag.2007.10.003
  32. 32. Grisold AJ, Wendelin I, Presterl E, Raggam RB, Masoud L, Badura A, et al. In vitro activity of ten antibiotics, including tigecycline, against Bacteroides species in Austria. European Journal of Clinical Microbiology & Infectious Diseases. [journal article]. 2007;26(7):525-7.10.1007/s10096-007-0318-017562088
  33. 33. Novak A, Rubic Z, Dogas V, Goic-Barisic I, Radic M, Tonkic M. Antimicrobial susceptibility of clinically isolated anaerobic bacteria in a University Hospital Centre Split, Croatia in 2013. Anaerobe. 2015;31:31-6.10.1016/j.anaerobe.2014.10.01025479237
  34. 34. Székely E, Eitel Z, Molnár S, Szász IÉ, Bilca D, Sóki J. Analysis of Romanian Bacteroides isolates for antibiotic resistance levels and the corresponding antibiotic resistance genes. Anaerobe. 2015;31:11-4.10.1016/j.anaerobe.2014.09.00125218409
  35. 35. Kierzkowska M, Majewska A, Sawicka-Grzelak A, Mlynarczyk A, Chmura A, Kwiatkowski A, et al. Antibiotic resistance profiles of strictly anaerobic Gram-negative Bacteroides spp. and Parabacteroides spp. bacilli isolated from infected inpatients on surgical wards. Journal of Global Antimicrobial Resistance. 2016;7:128-9.10.1016/j.jgar.2016.09.00127770692
  36. 36. Jeverica S, Kolenc U, Mueller-Premru M, Papst L. Evaluation of the routine antimicrobial susceptibility testing results of clinically significant anaerobic bacteria in a Slovenian tertiary-care hospital in 2015. Anaerobe. 2017;47:64-9.10.1016/j.anaerobe.2017.04.00728433670
DOI: https://doi.org/10.2478/orvtudert-2018-0003 | Journal eISSN: 2537-5059 | Journal ISSN: 1453-0953
Language: English
Page range: 19 - 25
Submitted on: Jun 29, 2017
Accepted on: May 10, 2018
Published on: Jan 25, 2019
Published by: Transylvanian Museum Society
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year

© 2019 Sóki József, és Székely Edit, published by Transylvanian Museum Society
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.